Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-17166864 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| JNJ-17166864 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| JNJ-17166864 | DRUG | JNJ-17166864 0.5 mg per nostril twice daily for 2 weeks. |
| Placebo | DRUG | Placebo nasal spray twice daily for 2 weeks. |
Inclusion Criteria: * Have a clinical history of seasonal allergic rhinitis with onset and offset of nasal allergy symptoms during each of the past 2 mountain cedar allergy seasons * Have positive prick skin test reaction to mountain cedar allergen at screening or have a documented positive prick s...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | N/A | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | Undisclosed |
JNJ-17166864 is an investigational small molecule being developed for the treatment of allergic rhinitis. It is administered intranasally and has been studied in adults with allergic rhinitis. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
JNJ-17166864 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with allergic rhinitis.
JNJ-17166864 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug remains investigational and has not received FDA approval for any indication.
JNJ-17166864 has been studied in one clinical trial, identified as NCT00604123. This Phase 2 study evaluated the effects of intranasal JNJ-17166864 on symptoms of allergic rhinitis in adults. The trial was completed in the United States and enrolled 74 participants.
The specific molecular target of JNJ-17166864 has not been disclosed. It is a small molecule administered intranasally for the treatment of allergic rhinitis. The exact mechanism of action is not publicly available from the clinical trial information provided.